Publications by authors named "Mrigender Singh Virk"
Background: Blood product constraints have increased the focus on inventory management as blood banks have faced challenges that impact supply chains and donor availability. Solutions often include a reduction in transfusion volumes through multidisciplinary improvements, but this is often coupled with a reduction in blood bank inventory to match reduced demand. We sought to improve inventory availability within the blood bank without modification of transfusion rates through solutions that prevented unnecessary RBC orders and crossmatching.
View Article and Find Full Text PDFObjectives: Cryoprecipitated antihemophilic factor (cryo) has been used for fibrinogen replacement in actively bleeding patients, dysfibrinogenemia, and hypofibrinogenemia. Cryo has a shelf life of 4 to 6 hours after thawing and a long turnaround time in issuing the product, posing a major limitation of its use. Recently, the US Food and Drug Administration approved Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex [IFC]) for the treatment of bleeding associated with fibrinogen deficiency, which can be stored at room temperature and has a shelf life of 5 days after thawing.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on the identification of red blood cell antibodies, which is crucial in transfusion medicine to prevent serious complications.
- Researchers analyzed 631,535 antibody screens over 15 years at Stanford, comparing the effectiveness of two testing methods: tube (PEG-IAT) and solid-phase assays.
- The results showed a low rate of discordant results between the two methods, but certain antibodies like anti-Jka and anti-E were more reliably detected by one method over the other, highlighting the need for careful method selection in clinical practice.
Article Synopsis
- The study investigates the impact of serologic reactivity of unidentified specificity (SRUS) during pregnancy on the risk of hemolytic disease of the fetus and newborn (HDFN).
- Over an 11-year period, data from 284 pregnancies with SRUS were analyzed, revealing that most cases of SRUS were not associated with HDFN, even in the presence of ABO incompatibility or other identifiable antibody reactions.
- The findings suggest that while SRUS alone does not indicate HDFN risk, it can occasionally precede clinically significant antibodies linked to HDFN.